Renalytix PLCNASDAQ:RNLXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.4301
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.4301/ 2
- Ask / Lots0.4349/ 8
- Open / Previous Close0.0000 / 0.4301
- Day Range---
- 52 Week Range
- Volume1,956
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RNLX |
|---|---|---|
| 09:32 ET | 7332 | 0.4649 |
| 09:34 ET | 1633 | 0.4628 |
| 09:36 ET | 6424 | 0.4501 |
| 09:38 ET | 1143 | 0.4501 |
| 09:39 ET | 2194 | 0.4401 |
| 09:43 ET | 1100 | 0.4401 |
| 09:52 ET | 100 | 0.4351 |
| 09:54 ET | 100 | 0.4401 |
| 09:59 ET | 250 | 0.44 |
| 10:03 ET | 2895 | 0.46 |
| 10:06 ET | 2100 | 0.45 |
| 10:10 ET | 100 | 0.441 |
| 10:12 ET | 100 | 0.441 |
| 10:15 ET | 100 | 0.441 |
| 10:33 ET | 631 | 0.45 |
| 10:35 ET | 1100 | 0.4507 |
| 10:37 ET | 1000 | 0.4507 |
| 10:42 ET | 400 | 0.4601 |
| 10:51 ET | 8276 | 0.441 |
| 10:55 ET | 291 | 0.45882 |
| 10:57 ET | 450 | 0.441101 |
| 11:04 ET | 300 | 0.4411 |
| 11:13 ET | 120 | 0.441 |
| 11:26 ET | 104 | 0.441 |
| 11:29 ET | 723 | 0.4583 |
| 11:38 ET | 100 | 0.45 |
| 11:40 ET | 200 | 0.45 |
| 11:42 ET | 25811 | 0.443 |
| 11:44 ET | 2548 | 0.441 |
| 11:45 ET | 500 | 0.44 |
| 12:03 ET | 200 | 0.462 |
| 12:16 ET | 393 | 0.4431 |
| 12:21 ET | 630 | 0.444 |
| 12:30 ET | 1635 | 0.4534 |
| 12:34 ET | 522 | 0.443 |
| 12:36 ET | 2000 | 0.444 |
| 12:39 ET | 2800 | 0.4432 |
| 01:03 ET | 438 | 0.443 |
| 01:10 ET | 15922 | 0.4433 |
| 01:12 ET | 1100 | 0.44 |
| 01:17 ET | 2942 | 0.451051 |
| 01:19 ET | 332 | 0.44 |
| 01:33 ET | 636 | 0.44 |
| 01:42 ET | 500 | 0.4449 |
| 01:46 ET | 1107 | 0.4498 |
| 01:50 ET | 1007 | 0.4401 |
| 01:53 ET | 100 | 0.4498 |
| 02:00 ET | 2594 | 0.4401 |
| 02:02 ET | 12845 | 0.4351 |
| 02:09 ET | 18446 | 0.4299 |
| 02:11 ET | 2100 | 0.4295 |
| 02:13 ET | 540 | 0.43 |
| 02:15 ET | 300 | 0.43 |
| 02:18 ET | 1700 | 0.4316 |
| 02:20 ET | 1700 | 0.43 |
| 02:24 ET | 200 | 0.4284 |
| 02:27 ET | 1900 | 0.4249 |
| 02:29 ET | 1600 | 0.42 |
| 02:31 ET | 39005 | 0.4101 |
| 02:33 ET | 100 | 0.4149 |
| 02:36 ET | 1200 | 0.414 |
| 02:38 ET | 306 | 0.4166 |
| 02:45 ET | 500 | 0.4187 |
| 02:49 ET | 200 | 0.416777 |
| 02:56 ET | 100 | 0.4166 |
| 02:58 ET | 616 | 0.4141 |
| 03:00 ET | 700 | 0.4142 |
| 03:05 ET | 2200 | 0.4142 |
| 03:07 ET | 300 | 0.414899 |
| 03:12 ET | 263 | 0.415 |
| 03:14 ET | 3500 | 0.4165 |
| 03:16 ET | 300 | 0.4141 |
| 03:21 ET | 205 | 0.4148 |
| 03:25 ET | 1100 | 0.4147 |
| 03:27 ET | 300 | 0.4147 |
| 03:34 ET | 1062 | 0.4149 |
| 03:39 ET | 1200 | 0.4125 |
| 03:41 ET | 3700 | 0.42 |
| 03:48 ET | 6135 | 0.4222 |
| 03:50 ET | 16600 | 0.4179 |
| 03:52 ET | 1800 | 0.4169 |
| 03:54 ET | 8800 | 0.4251 |
| 03:56 ET | 500 | 0.4278 |
| 03:57 ET | 100 | 0.4289 |
| 03:59 ET | 1000 | 0.4301 |
May 15, 2024
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024, from 7:00AM ET on Wednesday May 15, 2024 by Dow Jones
7:00AM ET on Wednesday May 15, 2024 by Dow JonesPress Release: Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024, from 7:00AM ET on Wednesday May 15, 2024 by Dow Jones
7:00AM ET on Wednesday May 15, 2024 by Dow Jones
May 9, 2024
Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15, from 7:00AM ET on Thursday May 09, 2024 by Dow Jones
7:00AM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Renalytix PLC | 37.4M | -0.5x | --- |
Neuroone Medical Technologies Corp | 27.1M | -1.7x | --- |
Icecure Medical Ltd | 47.6M | -3.3x | --- |
Akili Inc | 32.9M | -0.7x | --- |
Positron Corp | 30.4M | -13.1x | --- |
Autonomix Medical Inc | 38.7M | -4.1x | --- |
Company Information
Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. It is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Contact Information
- Headquarters
- Finsgate, 5-7 Cranwood StreetLONDON, United Kingdom EC1V 9EE
- Phone
- 292-071-0570
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $37.4M |
|---|---|
Revenue (TTM) | $2.2M |
Shares Outstanding | 77.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.87 |
EPS | $-0.78 |
Book Value | $0.15 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 16.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,531.61% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
